ProKidney Statistics
Total Valuation
ProKidney has a market cap or net worth of $595.65 million. The enterprise value is $328.16 million.
Important Dates
The next estimated earnings date is Monday, March 16, 2026, before market open.
| Earnings Date | Mar 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ProKidney has 300.83 million shares outstanding. The number of shares has increased by 60.61% in one year.
| Current Share Class | 141.55M |
| Shares Outstanding | 300.83M |
| Shares Change (YoY) | +60.61% |
| Shares Change (QoQ) | +3.26% |
| Owned by Insiders (%) | 17.81% |
| Owned by Institutions (%) | 15.79% |
| Float | 93.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 800.61 |
| Forward PS | 7,007.95 |
| PB Ratio | 1.87 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 441.08 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.32, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.32 |
| Quick Ratio | 9.39 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -34,177.80 |
Financial Efficiency
Return on equity (ROE) is -41.81% and return on invested capital (ROIC) is -27.65%.
| Return on Equity (ROE) | -41.81% |
| Return on Assets (ROA) | -25.85% |
| Return on Invested Capital (ROIC) | -27.65% |
| Return on Capital Employed (ROCE) | -52.98% |
| Weighted Average Cost of Capital (WACC) | 14.18% |
| Revenue Per Employee | $3,647 |
| Profits Per Employee | -$348,201 |
| Employee Count | 204 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ProKidney has paid $3.70 million in taxes.
| Income Tax | 3.70M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +23.75% in the last 52 weeks. The beta is 1.82, so ProKidney's price volatility has been higher than the market average.
| Beta (5Y) | 1.82 |
| 52-Week Price Change | +23.75% |
| 50-Day Moving Average | 2.26 |
| 200-Day Moving Average | 2.12 |
| Relative Strength Index (RSI) | 37.22 |
| Average Volume (20 Days) | 1,050,346 |
Short Selling Information
The latest short interest is 15.25 million, so 5.07% of the outstanding shares have been sold short.
| Short Interest | 15.25M |
| Short Previous Month | 15.18M |
| Short % of Shares Out | 5.07% |
| Short % of Float | 16.35% |
| Short Ratio (days to cover) | 12.42 |
Income Statement
In the last 12 months, ProKidney had revenue of $744,000 and -$71.03 million in losses. Loss per share was -$0.54.
| Revenue | 744,000 |
| Gross Profit | 744,000 |
| Operating Income | -170.89M |
| Pretax Income | -155.54M |
| Net Income | -71.03M |
| EBITDA | -164.58M |
| EBIT | -170.89M |
| Loss Per Share | -$0.54 |
Full Income StatementBalance Sheet
The company has $271.73 million in cash and $4.24 million in debt, with a net cash position of $267.49 million or $0.89 per share.
| Cash & Cash Equivalents | 271.73M |
| Total Debt | 4.24M |
| Net Cash | 267.49M |
| Net Cash Per Share | $0.89 |
| Equity (Book Value) | 318.34M |
| Book Value Per Share | -7.41 |
| Working Capital | 270.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$111.78 million and capital expenditures -$34.95 million, giving a free cash flow of -$146.73 million.
| Operating Cash Flow | -111.78M |
| Capital Expenditures | -34.95M |
| Free Cash Flow | -146.73M |
| FCF Per Share | -$0.49 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -22,968.95% |
| Pretax Margin | -20,906.18% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ProKidney does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -60.61% |
| Shareholder Yield | -60.61% |
| Earnings Yield | -11.93% |
| FCF Yield | -24.63% |
Analyst Forecast
The average price target for ProKidney is $7.40, which is 273.74% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.40 |
| Price Target Difference | 273.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 347.47% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ProKidney has an Altman Z-Score of -1.73. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.73 |
| Piotroski F-Score | n/a |
